AI in Pharma: The New Playbook for Drug Research & Development

In this webinar, our expert breaks down AI’s impact across the entire R&D pipeline – from discovery to FDA approval.

AI is revolutionizing drug discovery, preclinical development, and clinical trials.

As it rapidly reshapes the pharmaceutical landscape, companies and investors must understand how to harness this maturing technology. In this session, we cover:

High momentum markets across the R&D pipeline
Shifting trends in AI-driven clinical trials and upcoming innovations
Strategies for pharma companies and investors to stay ahead

AI is reshaping the future of drug development. Don’t miss out on where the biggest opportunities lie.

Your panel

Ellen Knapp

Senior Intelligence Analyst

Ellen Knapp is a healthcare analyst at CB Insights with an emphasis on emerging therapeutics.

Before joining the CB Insights team, Ellen worked in early-stage oncology drug development at Pfizer where she focused on enabled formulations and biopharmaceutics modeling.

Ellen received her PhD in Chemical Engineering from The City College of New York with a thesis focused on colloids and interfacial science.

Ellen Knapp is a healthcare analyst at CB Insights with an emphasis on emerging therapeutics.

Before joining the CB Insights team, Ellen worked in early-stage oncology drug development at Pfizer where she focused on enabled formulations and biopharmaceutics modeling.

Ellen received her PhD in Chemical Engineering from The City College of New York with a thesis focused on colloids and interfacial science.